S tudies of children with SCD from the 1960s to 1990s described poor growth and delayed skeletal and sexual maturation (1) (2) (3) (4) (5) , demonstrating low growth percentiles in height and weight among children older than 2 to 5 y of age, especially for children with type SCD-SS. Among studies conducted in the United States, only one was longitudinal (1), documenting short stature, poor weight gain, and delayed adolescent growth, particularly among males with SCD. The results of the Comprehensive Study of Sickle Cell Disease (CSSCD) (4), reporting on more than 2000 patients, confirmed many of these findings and showed that growth failure was unrelated to socioeconomic status, the onset and progression through puberty were delayed, and delayed menarche in girls was related to their low weight status. However, further effects of disease related factors on growth failure were not investigated.
There has been a paucity of studies designed to identify the causes of and treatment strategies for suboptimal growth and pubertal delay in SCD. Advances in the clinical care of children with SCD, such as earlier diagnosis, penicillin prophylaxis, folate supplementation, and transfusion and hydroxyurea therapy, have reduced morbidity and mortality. However, the prevalence of suboptimal growth and its relationship to disease severity has not been evaluated in a contemporary cohort of U.S. children. Growth status remains an important indicator of the overall health and well-being of the child. We hypothesized that nutritional status and disease severity were significant predictors of growth failure assessed prospectively in children with SCD-SS. The present study describes longitudinal patterns of growth in a group of children with SCD cared for in a comprehensive sickle cell center and identifies potentially remediable factors associated with suboptimal growth.
METHODS

Subjects.
All eligible children with SCD-SS receiving care at a comprehensive sickle cell center were invited to participate. Children ages birth to 18 y were eligible if they did not have other significant chronic illnesses (e.g. cystic fibrosis, moderate to severe cerebral palsy, Down syndrome), were not taking medications known to affect growth or nutritional status (e.g. growth hormone, glucocorticoid therapy), and were not taking hydroxyurea. Children receiving chronic transfusion therapy after a stroke were included. SCD-SS genotype was determined by standard hemoglobin (Hgb) separation studies including electrophoresis and high-pressure liquid chromatography. The study protocol was approved by the Committee for the Protection of Human Subjects of The Children's Hospital of Philadelphia. Informed consent was obtained from parents or guardians and assent from children ages 7 y and older.
Procedures. Children were evaluated at baseline (visit 1) and annually for 4 y (visits 2-5) in conjunction with a regularly scheduled office visit. A research anthropometrist obtained measurements of length or stature using an infantometer or digital stadiometer (Holtain, Crymych, UK), weight using an infant or stand-on digital electronic scale (Scaletronix, White Plains, NY), mid-upper arm circumference, and skinfold thicknesses at the triceps, biceps, subscapular, and suprailiac sites using skinfold calipers (Holtain, Crymych, UK) following standard techniques (6).
Puberty status was determined using a self-assessment questionnaire (7) that contained pictorial representations and written descriptions of Tanner's stages of breast, genital, and pubic hair development (8) . This method has previously been validated in our laboratory (9) . Menarcheal status and age at first menstruation information was elicited from girls, 9 y of age and older. Bone age, determined at visit 2 from a left hand-wrist radiograph, was assessed by a single investigator (B.S.Z.) using the Tanner Whitehouse III method (10) . Bone age delay (years) was calculated as bone age minus chronological age.
Blood samples were analyzed for Hgb concentration, hematocrit (Hct), reticulocyte count, fetal Hgb level (HgbF) (visits 3-5 only), and platelet and white blood cell (WBC) counts (Clinical Laboratory, Children's Hospital of Philadelphia). For children receiving long-term transfusion therapy, blood samples were obtained just before transfusion. For statistical analyses, hematological indices and nutritional status Z scores (arm circumference, triceps and upper arm fat area Z scores) were transformed to eliminate skewness, but the results with the nontransformed values are shown. Dietary intake was obtained at visits 2 through 5 using the 24-h recall method and computer analyzed (Food Processor, ESHA Research, Inc., Salem, OR). Total energy intake, protein intake, and percentage of energy from fat were determined. Transfusion status, health history, and family information, including education status of the primary caretaker and household income were elicited by questionnaire. Because many families did not know their annual household income, only the education status of the primary caretaker (hereafter, maternal education) was used in the analyses. Number of SCD-related hospitalizations and total days of hospitalization in the year before and after each study visit were provided by the Comprehensive Sickle Cell Center database.
Statistical analysis Standard deviation (SD) scores (Z scores) and percentile rank for length, height, weight, and body mass index (BMI) were based on U.S. growth charts (11) . Growth failure was defined as a height, weight, or BMI measurement below the 5th percentile. Upper arm muscle area and upper arm fat area were derived from the mid-upper arm circumference and triceps skinfold thickness measures (12) . Z scores for arm circumference, triceps skinfold thickness, upper arm muscle area, and upper arm fat area were based on National Center for Health Statistics reference data (12) .
Means and SDs were calculated using the XTSUM feature in STATA 9.0 (College Station, TX) to account for the mixed longitudinal design and repeat observations. Cross-sectional comparisons were performed using t test for normally distributed data, and by the Mann-Whitney test for skewed data. Median age at menarche and at entry into the Tanner stages of sexual development (pubic hair and breast or genital development) was computed using the XTPROBIT feature in STATA.
Longitudinal analyses of growth Z scores were performed using the longitudinal mixed effects analysis procedure in STATA (XTREG). Basic models were tested separately by gender to determine age trends, changes over time, and the effect of puberty. Additional variables were added to the model to determine whether puberty disease severity indicators (Hgb concentration, Hct, fetal HgbF level, hospitalizations, transfusion status, WBC counts), dietary intake (energy, protein, percentage of energy from fat), or maternal education were significantly associated with changes in growth status over time. For height Z score, nutritional status (upper arm muscle area Z, upper arm fat area Z) variables were added to the models. Children receiving transfusion therapy were excluded from some analyses because of the known effects of transfusion therapy on the hematological indices of disease severity. Final models were selected on the basis of maximum R 
RESULTS
Sample description.
One hundred forty-eight children (78 females), ages birth to 18 y, with SCD-SS were enrolled and evaluated annually for 4 y. The total number of visits was 578. The average annual attrition rate was 12% per year over 4 y. Children who dropped out of the study were significantly older at baseline than those who remained enrolled (9.7 versus 6.3 y, p Ͻ 0.0001). However, they did not differ in growth pattern, hematological status, or maternal education level.
At baseline, 11% of subjects (n ϭ 17) were receiving long-term blood transfusion therapy. In the final year, 16% of the sample (n ϭ 14) received long-term blood transfusion therapy. Children who received transfusion therapy were 1.4 y older, on average (p Ͻ 0.01), and, as expected, had higher Hgb (9.0 versus 7.9 mg/dL, p Ͻ 0.001) and Hct (26 versus 23%, p Ͻ 0.001) levels, and lower HgbF levels (2.2 versus 9.8%, p Ͻ 0.001) than those not receiving transfusion therapy. However, they did not differ in growth status as indicated by height, weight, or BMI Z scores.
Skeletal and sexual maturation. Bone age was determined for 106 subjects (51 females) at the second visit, representing 78% of those who returned for the second visit. Those who completed the bone age evaluation were more likely to be older (9.3 versus 7.0 y, p ϭ 0.02) and male (87% of males versus 71% of females, p ϭ 0.02), but they did not differ in disease severity measures, growth or nutritional status, or maternal education. The median bone age delay was Ϫ0.4 y [interquartile range (IQR): Ϫ1.67 to 0.4 y). For children 10 to 15 y of age (n ϭ 33), the median bone age delay was Ϫ1.3 y (IQR, Ϫ2.4 to 0.1 y). In this older age range, boys had a greater delay in bone age than girls (Ϫ1.7 Ϯ 1.4 y versus -0.6 Ϯ 1.5 y, respectively, p ϭ 0.04). On average, the delay in bone age was less among children receiving transfusion therapy compared with those who did not, particularly in the 10-to 15-y age range (median: Ϫ0.3 versus Ϫ1.8, p ϭ 0.04).
Puberty status was also delayed (Table 1 ). For girls, median age at menarche was 13.2 y. The median age of girls in stages 2 through 4 for breast stage and pubic hair development was 1 to 2 y delayed in comparison to recently published data from the National Health and Nutrition Examination Survey (NHANES) III (13) for non-Hispanic black children. For boys, a similar pattern of delay was observed for genital and pubic hair development. The median ages of children in Tanner stages 2-4 were similar to those reported by the CSSCD. Transfusion status did not have a notable effect on pubertal development.
Disease severity indicators and growth status. Hgb concentration, Hct, and HgbF level were in the range typically seen for children with SCD-SS. Excluding children receiving transfusion therapy, boys had lower Hct and HgbF levels than girls (Table 2 ). For the group overall (including subject receiving transfusion therapy), growth status was poor as indicated by the Z scores for height, weight, and BMI (Table 2) . Boys had significantly lower Z scores for weight, length/ height, arm circumference, arm muscle area, and arm fat area than girls. Transfusion status was not associated with growth status, but boys receiving transfusion therapy had significantly greater mid-upper arm circumference (median: Ϫ0.6 versus Ϫ1.5, p ϭ 0.02) and upper arm fat area (median: Ϫ0.5 versus Ϫ1.3, p ϭ 0.01) Z scores compared with other boys.
For all children, the percentage of subjects who exhibited growth failure (Յ5th percentile) at any time during the study was 26%, 22%, and 24%, for weight, height, and BMI, respectively (Fig. 1) . Thirty-eight percent of subjects exhibited growth failure at any time for any of the three growth measures. Boys were more likely to have growth failure than girls for all measures. Moreover, the majority of children failed to maintain their growth status established at visit 1 and experienced a negative change in growth Z scores. From study entry to the last visit, 70% of children declined in length/ height Z score, 59% declined in weight Z score, and 55% 608 declined in BMI Z score. Overall, 84% of children declined in one or more of these growth indicators.
Longitudinal patterns of growth. Longitudinally, length/ height and weight Z scores declined with age for both males and females (Fig. 2) . Among younger children, mean Z scores for height and weight were close to zero (i.e. almost normal) and declined with age. Age at enrollment was negatively associated with height and weight Z scores due to the age- The age characteristics of children in each Tanner Descriptive statistics are shown for growth, nutritional status, and hematological measures for the entire sample and for boys and girls separately. The data presented are mixed longitudinal. The between-subjects SD and the total number of observations for each measure are shown. BMI Z scores were calculated for children 2 y of age and older. The p values are for gender comparisons adjusting for multiple observations per subject. * Number of observations over 4 y. † Excludes subjects receiving transfusion. IQR, interquartile range.
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associated deficits in growth status (Table 3 ). Further declines in growth status occurred over time. For girls, transfusion therapy was associated with improved growth status over time, but not for boys. After adjustment for puberty stage in girls, transfusion status was not associated with changes in growth status over time (results not shown). To assess the effect of disease related parameters on growth, the analyses were restricted to nontransfused subjects only. The results for girls are summarized as follows: length/ height and weight Z scores decreased at a rate of Ϫ0.08 and -0.05 Z score units per year, respectively, after adjustment for the baseline age-related decline (models not shown). Addition of other factors to the model attenuated these declines. The positive and progressively increasing coefficients for Tanner stage indicated that with the advancement of puberty, height, weight, and BMI Z scores improved. Hgb and Hct concentrations were positively associated with length/height Z scores, and Hgb and HgbF concentrations were associated with weight and BMI Z scores over time. There were no associations of reticulocyte count, platelets, SCD-related hospitalizations, maternal education, or dietary intake on length/height status in females. Nutritional status indicators (upper arm muscle area and upper arm fat area Z scores) were subsequently added to the model for height Z score (Table 3) . Upper arm muscle area was positively and significantly associated with height Z score over time in girls in addition to puberty status and Hgb concentration. For weight and BMI Z score, the best fitting model included maternal education level, along with HgbF, age, puberty status, and time. HgbF was measured in y 3-5 only, so these results are based on more limited numbers of observations. However, similar results were obtained using Hgb, albeit with lower R 2 values (R 2 ϭ 0.30 for weight Z score and R 2 ϭ 0.15 for BMI Z score). For boys, age at enrollment was negatively associated with length/height and weight Z scores, signaling the age-related decline in growth status that was present at baseline. After adjustment for the baseline age-related decline, height, weight, and BMI Z scores declined and growth status deteriorated over time (Ϫ0.01, Ϫ0.5, and Ϫ0.07 Z score units per year, respectively). Pubertal development was not associated with growth status, nor was transfusion status. Measures of hematological status (Hgb, Hct, HgbF, reticulocyte count, platelets, WBC counts), SCD-related hospitalizations, and dietary intake were not related to changes in growth status over time (Table 3) . Upper arm muscle area Z score, a nutritional status indicator, was a significant predictor of height Z score and attenuated the effects of initial age and time on the longitudinal changes in height status.
DISCUSSION
Previous studies of children and adolescents with SCD were conducted up to several decades ago and demonstrated impaired growth in height and weight (1-4,14 -16 ). More recently, a survey of 63 children with SCD in Baltimore published in 1994 reported that 25% were lower than the 5th percentile for either height for age, weight for age, or weight for height (14) . The longitudinal data presented here, collected from 1993 to 1999, provide insights into the pattern and magnitude of growth failure in a contemporary group of children with SCD receiving care in a comprehensive sickle cell center in the United States. In this prospective study of a large sample of children with SCD-SS, 38% of subjects were below the 5th percentile at some point during the 4 y of the study, a commonly used screening criterion for growth failure in healthy children meriting clinical concern. However, using the criterion of failure to maintain baseline growth status, 84% of subjects experienced a decline in one or more growth indicators. The prevalence of growth failure was age dependent and worsened with age in most subjects. Thus, most children with SCD experience growth failure at some point.
Previous studies in the 1980s of young children with SCD-SS showed that at birth, infants were normal in size, but by 2-5 y of age, significant deficits were apparent (2,3), and we observed a similar pattern. In addition, our data showed that the decline was unrelenting throughout childhood and adolescence for males, especially for weight and BMI, whereas for females, growth status in length/height and weight declined during childhood and some recovery occurred with the onset of puberty. Although the sample of SCD-SS was small, Phebus et al. (1) also noted some improvement in growth status of females after age 12 y.
Delayed sexual and skeletal maturation in children with SCD (2,4,16 -19 ) was evident in this sample, as in previous samples of children with SCD, and may account, in part, for Final models for the longitudinal mixed effects analysis predicting changes in growth status over time. Initial models were developed based on the effects of age at entry into the study to evaluate cross-sectional age effects; further declines in growth status that occurred over time after visit 1 are denoted by the variable "time" representing time since study entry. Tanner stage for breast development (girls) and genital development (boys) were entered into the models as a series of dummy variables with each stage compared to Tanner stage 1. The effects of disease severity, dietary intake, and maternal education status were also tested among subjects who were not receiving long-term transfusion therapy. Only the final models are shown.
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the observed growth deficits. The age at menarche (13.2 y) was later than the reported age in the NHANES III survey (13) for non-Hispanic black girls (mean: 12.4 y, 95% confidence interval: 12.2-12.5). Compared with this survey, the median ages of children with SCD in Tanner stages 2-4 were 1-2 y older and similar to the children with SCD-SS in the CSSCD report (4). Singhal et al. (16) observed similar delays in the age at peak height velocity of boys and girls with SCD in Jamaica, another indicator of delayed pubertal development. In our study, the U.S. boys and girls with SCD-SS were comparably delayed in sexual maturation relative to national norms, but the effect of the delay on growth differed. The longitudinal regression models consistently indicated that girls experienced some growth recovery with the onset and progression through puberty, whereas for boys, there was no positive effect of puberty on growth. The reason for gender differences in the magnitude of growth deficits and the overall pattern of longitudinal changes in growth status is unknown. Others have also reported more severe growth deficits in boys with SCD compared with girls (1, 15) . Abnormalities in gonadotropin secretion patterns (elevated luteinizing hormone and depressed follicle-stimulating hormone in early puberty) in boys and girls with SCD (19) and poor testosterone response to gonadotrophin-releasing hormone in some boys (20) suggest impairments in the regulatory feedback mechanisms of the hypothalamic-pituitary-gonadal axis leading to sexual maturity. Growth hormone abnormalities have also been reported (21) (22) (23) .
Disease severity is difficult to define for SCD. SCD-related hospitalizations, long-term transfusion therapy, and measures of steady-state hematological status were used as markers of disease severity. Hgb, Hct, and/or HgbF were associated longitudinally with height, weight, and BMI Z scores in girls, but not boys. Girls had significantly greater Hgb, Hct, and HgbF than boys, and these measures were predictive of longitudinal changes in height, weight, and BMI status in girls. The reason for this gender difference is unknown. Interestingly, among prepubertal Jamaican children, Singhal et al. (24) found that Hgb concentration was associated with height and weight in males, but not females. In addition, significant improvements in linear growth were noted after splenectomy in Jamaican children (25) . Evaluation of the effects of hydroxyurea therapy on growth status has not revealed a statistically significant benefit, nor an adverse effect on growth; maintenance or modest improvements in growth percentiles have been suggested (26, 27) . In the Stroke Prevention Trial for Sickle Cell Anemia Study (STOP Trial), a well-controlled long-term transfusion therapy protocol, height, weight, and BMI Z scores improved significantly in those receiving transfusions, whereas there were no changes in growth status in the control group. After 24 mo of treatment, children in the transfusion group approached normal height for age and weight for age Z scores (28). We did not find an effect of transfusion therapy on changes in growth status over time, but children receiving longterm transfusion therapy had less severe bone age delay, and males had better anthropometric measures of nutritional status. In our study, the duration of transfusion therapy was not assessed, was likely variable among subjects, and was not provided under the controlled conditions of a research protocol. Therefore, this study had limited ability to assess the effects of long-term transfusion therapy on growth and sexual maturation. In sum, the longitudinal regression analyses suggest that growth status reflects the long-term effects of severe anemia, undernutrition, and other (e.g. maternal education) factors rather than the acute effects of SCD-related complications that lead to hospitalizations and long-term transfusion therapy.
Nutritional studies of children with SCD have identified numerous deficits that likely contribute to growth failure. In this study, energy, protein, and fat intake were not associated with growth failure, although a single 24-h recall of dietary intake per year is not an accurate assessment of macronutrient intake for an individual. Increased energy requirements have been reported for children, teenagers, and adults (29 -31) with SCD in their usual state of health. Increased protein turnover adds an additional nutritional burden (29, 32) . Nutrient deficiencies based on biomarkers have been reported for vitamins B 6 (33, 34) , D (35) , and E (36,37); retinol (38) ; and zinc (39 -41) . In a 12-mo trial, zinc supplementation was shown to increase linear growth in children with SCD-SS (40) . However, there are remarkably few supplementation or general nutrition intervention studies aimed at improving growth or nutritional status in children with SCD.
The findings reported here indicate that growth failure and delayed maturation remain clinically significant problems in children with SCD-SS, the more common and clinically severe form of the disease. Failure to maintain a growth trajectory was almost universal, and 38% of children fell below the 5th percentile for weight, height, or BMI at least once during this 4-y observation period. The 5th percentile was developed as a criterion for screening healthy children for growth failure, and we suggest that is not the optimal criterion for screening children with a chronic disease with known nutritional risks. Increased energy and micronutrient requirements and endocrine abnormalities have been reported and merit future study to determine their role in the etiology and treatment of growth and developmental delay in SCD. Growth failure likely reflects malnutrition (protein, energy, and micronutrient deficits) in the growing child and adolescent with SCD and the longterm effects of severe anemia. Further research is needed to develop effective intervention strategies to achieve and maintain optimal growth and sexual and skeletal maturation in children and adolescents with SCD-SS.
